Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide

被引：0
|
作者：
Orkin, Chloe [1 ]
Antinori, Andrea [2 ]
Rockstroh, Juergen [3 ]
Guillen, Santiago Moreno [4 ]
Martorell, Claudia [5 ]
Molina, Jean-Michel [6 ]
Lazzarin, Adriano [7 ]
Maggiolo, Franco [8 ]
Yazdanpanah, Yazdan [9 ]
Andreatta, Kristen [10 ]
Huang, Hailin [10 ]
Hindman, Jason [10 ]
Martin, Hal [10 ]
Baeten, Jared [10 ]
Pozniak, Anton [11 ]
机构：
[1] Queen Mary Univ London, London, England
[2] Natl Inst Infect Dis, Lazzaro Spallanzani, Rome, Italy
[3] Univ Hosp Bonn, Bonn, Germany
[4] Hosp Ramon & Cajal, Madrid, Spain
[5] Res Inst Springfield, Springfield, MO USA
[6] Univ Paris, Paris, France
[7] San Raffaele Hosp Milan, Milan, Italy
[8] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy
[9] AP HP Hop Bichat, Paris, France
[10] Gilead Sci Inc, Foster City, CA USA
[11] Chelsea & Westminster Hosp, London, England
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P002
引用
收藏
页码：21 / 22
页数：2
相关论文
共 50 条
  • [31] Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV
    De Socio, Giuseppe Vittorio
    Tordi, Sara
    Altobelli, Debora
    Gidari, Anna
    Zoffoli, Anastasia
    Francisci, Daniela
    Wozniacka, Anna
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (24)
  • [32] Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1
    Wei, Yinghua
    Li, Jin
    Xu, Ruhong
    Wen, Li
    Deng, Yiming
    He, Lixia
    Zhong, Huijun
    Wang, Yanhao
    CHINESE MEDICAL JOURNAL, 2023, 136 (22) : 2677 - 2685
  • [33] Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-na?ve adults with HIV-1
    Wei Yinghua
    Li Jin
    Xu Ruhong
    Wen Li
    Deng Yiming
    He Lixia
    Zhong Huijun
    Wang Yanhao
    中华医学杂志英文版, 2023, 136 (22)
  • [34] Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
    Gan, Lin
    Xie, Xiaoxin
    Fu, Yanhua
    Yang, Xiaoyan
    Ma, Shujing
    Kong, Linghong
    Song, Chunli
    Song, Yebing
    Ren, Tingting
    Long, Hai
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (11) : 2581 - 2593
  • [35] Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study
    Brar, Indira
    Ruane, Peter J.
    Berhe, Mezgebe
    Brinson, Cynthia
    Benson, Paul
    Henry, Keith
    Liu, Hui
    Andreatta, Kristen
    Hindman, Jason T.
    Ramgopal, Moti
    MEDICINE, 2025, 104 (08)
  • [36] Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice
    Ciccullo, Arturo
    Baldin, Gianmaria
    Borghi, Vanni
    Oreni, Letizia
    Lagi, Filippo
    Fusco, Paolo
    Giacomelli, Andrea
    Torti, Carlo
    Sterrantino, Gaetana
    Mussini, Cristina
    Antinori, Spinello
    Di Giambenedetto, Simona
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (01)
  • [37] Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide
    Scevola, Sofia
    Niubo, Jordi
    Domingo, Pere
    Verdejo, Guillermo
    Curran, Adrian
    Diaz-Brito, Vicens
    Penafiel, Judith
    Tiraboschi, Juan
    Morenilla, Sandra
    Garcia, Benito
    Soriano, Irene
    Podzamczer, Daniel
    Imaz, Arkaitz
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 (07): : 919 - 925
  • [38] Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir
    Calza, Leonardo
    Bon, Isabella
    Pensalfine, Giulia
    Vitale, Salvatore
    Appolloni, Lucia
    Viale, Pierluigi
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 91 (04) : E9 - E11
  • [39] HIV-1 viral decay in blood and semen in antiretroviral-naive adults initiating dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide
    Wang, Ran
    Liu, Yongjian
    Sun, Lijun
    Li, Aixin
    Lv, Shiyun
    Zhai, Yuanyi
    Li, Rui
    Hua, Wei
    Wang, Xi
    Li, Lin
    Dai, Lilli
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 121 - 121
  • [40] Metabolic effects of switching to tenofovir alafenamide/emtricitabine/bictegravir (B/F/TAF) from tenofovir difumarate (TDF) or tenofovir alafenamide (TAF) sparing regimens: METABIC study
    Busca, C.
    Ortega, D.
    Martin-Carbonero, L.
    Mican, R.
    Ramos, L.
    Valencia, M.
    Montejano, R.
    Montes, M.
    Diaz-Almiron, M.
    Delgado, A.
    Bernardino, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 150 - 151
12345